Macrophages and lymphocyte subpopulations in nifedipine- and cyclosporin A-associated human gingival overgrowth

Journal of Periodontology

Volumn 72, Issue 2, 2001, Pages 160-166

  Pernu, Hilkka E ^a   Knuuttila, Matti L E ^b  

^a UNIVERSITY OF OULU   (Finland)

^b NONE

Author keywords

Cells, CD labelled; Cyclospin A adverse effects; Gingival hyperplasia pathogenesis; Immune response; Lymphocytes; Macrophages; Nifedipine adverse effects

Indexed keywords

AVIDIN; BIOTIN; CD20 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; HORSERADISH PEROXIDASE; MONOCLONAL ANTIBODY; NIFEDIPINE;

ADULT; ANTIBODY LABELING; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; FEMALE; GINGIVA OVERGROWTH; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE; MOUTH MUCOSA; OUTPATIENT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; B-LYMPHOCYTES; CALCIUM CHANNEL BLOCKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CONNECTIVE TISSUE; CYCLOSPORINE; EPITHELIUM; FEMALE; GINGIVA; GINGIVAL OVERGROWTH; HEART DISEASES; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MACROPHAGES; MALE; NIFEDIPINE; STATISTICS; STATISTICS, NONPARAMETRIC;

EID: 0034967085     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2001.72.2.160     Document Type: Article

References (34)

1. Hassel TM, Hefti AF. Drug-induced gingival overgrowth: Old problem, new problem. Crit Rev Oral Biol Med 1991;2:103-137.
2. Russell RG, Graveley R, Coxon F, et al. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand J Rheumatol 1992;95(Suppl.):9-18.
3. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med 1991;20:201-209.
4. Pernu HE, Pernu LMH, Knuuttila MLE. Effect of periodontal treatment on gingival overgrowth among cyclosporine-A-treated renal transplant recipients. J Periodontol 1993;64:1098-1100.
5. Bökenkamp A, Bohnhorst B, Beier C, Albers N, Offner G, Brodehl J. Nifedipine aggravates cyclosporine A-induced gingival hyperplasia. Pediatr Nephrol 1994;8: 181-185.
6. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.
7. Birx DL, Berger M, Fleisher TA. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984;133:2904-2905.
8. Bono MR, Simon V, Rosemblatt MS. Blocking of human T lymphocyte activation by channel antagonists. Cell Biochem Func 1989;7:219-226.
9. 2 production and NK activity following nifedipine administration to healthy humans. Eur J Clin Pharmacol 1990;39: 545-550.
10. Bacon KB, Westwick J, Camp RDR. Potent and specific inhibition of IL-8-, IL-1α and IL-1β-induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun 1989;165:349-354.
11. Solovera JJ, Alvarez-Mon M, Casas J, Carballido J, Durantez A. Inhibition of human natural killer (MK) activity by calcium channel modulators and a calmodulin antagonist. J Immunol 1987;139:876-880.
12. Waschke K, von Baehr R, Wolf G. The action of calcium antagonists in human natural killer cell-mediated cytotoxicity. Allerg Immunol 1987;33:27-34.
13. Witkowski JM, Siebert J, Lukaszuk K, Trawicka L. Comparison of effects of a panel of membrane channel blockers on proliferative, cytotoxic and cytoadherence abilities of human peripheral blood lymphocytes. Immunopharmacol 1993;26:53-63.
14. Zahavi I, Notti I, Fishman P, Djaldetti M. The effect of nifedipine on protein synthesis and surface morphology of peripheral blood cells. Nouv Rev Fr Hematol 1986;28: 3-6.
15. Gelfand EW, Cheung RK, Grinstein S, Mills GB. Characterization of the role of calcium influx in mitogeninduced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. Eur J Immunol 1986;16:907-912.
16. Kakiuchi T, Mizuguchi J, Nariuchi H. Molecular analysis of the dissociation between IL-2 production and proliferation in a response of a T cell clone to the antigen presented by B cells. J Immunol 1988;141:3278-3284.
17. 2+ response and interleukin-2 production in Jurkat cells. J Leukoc Biol 1993;53:66-72.
18. Mahe Y, Wakasugi H, Scamps C, Chouaib S, Tursz T. Role of calcium on interleukin-1 production by monocytes: its relevance during T cell proliferation. Lymphokine Cytokine Res 1991;10:165-172.
19. Padberg WM, Bodewig H, Schäfer H, Muhrer KH, Schemmle K. Synergistic immunosuppressive effect of low-dose cyclosporine A and the calcium antagonist nifedipine, mediated by the generation of suppressor cells. Transplantation Proc 1990;22:2337.
20. Mandreoli M, Esposti ED, Cocchi R, Fabbri A, Guerrini L, Fusaroli M. Do calcium channel blockers have any influence on the immunological status of renal graft recipients on cyclosporin therapy? Am J Nephrol 1990; 10:58-60.
21. Marx M, Weber M, Merkel F, Mayer zum Büschenfelde KH, Köhler H. Additive effect of calcium antagonists on cyclosporin A-induced inhibition of T cell proliferation. Nephrol Dial Transplant 1990;5:1038-1044.
22. Hess AD, Esa AH, Colombani PM. Mechanisms of action of Cyclosporine: Effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988;20(Suppl. 2):29-40.
23. O'Valle F, Mesa FL, Có;mez-Morales M, et al. Immunohistochemical study of 30 cases of cyclosporine A-induced gingival overgrowth. J Periodontol 1994;65:724-730.
24. Plemons JM, Dill RE, Rees TD, Dyer BJ, Ng MC, lacopino AM. PDGF-B producing cells and PDGF-B gene expression in normal gingiva and cyclosporine A-induced gingival overgrowth. J Periodontol 1996;67:264-270.
25. Land W. Procedures and results in renal transplantation: Munich Transplant Centre 1986. In: Land W, ed. Optimal Use of Sandimmun in Organ Transplantation. Berlin: Springer-Verlag; 1987:21-24.
26. Thiel Q, Landmann J, Mihatsch MJ. Optimal use of Sandimmun in renal transplantation: The Basle experience. In: Land W, ed. Optimal Use of Sandimmun in Organ Transplantation. Berlin: Springer-Verlag; 1987: 25-29.
27. Jully JM, Béné MC, Martin G, Faure G. Immunohistological identification of cell subsets in human gingiva after local treatment for gingivitis or periodontitis. J Clin Periodontol 1986;13:223-227.
28. Meng H, Zheng L. T cells and T cell subsets in periodontal diseases. J Periodont Res 1989;24:121-126.
29. Murmenniemi PK, Pernu HE, Knuuttila MLE. Density of CD1-a labeled Langerhan's cells in normal human gingiva and in nifedipine- and immunosuppressive-medication-induced gingival overgrowth. J Periodontol 1999;70:752-756.
30. Topoll HH, Zwaldo G, Lange DE, Sorg C. Phenotypic dynamics of macrophage subpopulations during human experimental gingivitis. J Periodont Res 1989;24:106-112.
31. Gómez RS, Langer P, Pelka M, von den Driesch P, Johannessen AC, Simon M Jr. Variational expression of functionally different macrophage markers (27E10, 25F9, RM3/1) in normal gingiva and inflammatory periodontal disease. J Clin Periodontol 1995;22:341-346.
32. lacopino AM, Doxey D, Cutler CW, et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: Possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol 1997;68:73-83.
33. Takahashi K, Naito M, Takeya M. Development and heterogeneity of macrophages and their related cells through their differentation pathways. Pathol Int 1996;46: 473-485.
34. Nares S, Ng MC, Dill RE, Park B, Cutler CW, Iacopino AM. Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. J Periodontol 1996;67:271-278.